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Background: Glioblastoma is the most common and most aggressive form of malignant glioma and is very
difficult to treat. Controlling tumour cell invasion and angiogenesis is essential to improve the prognosis of
glioblastoma patients. Since constitutive activation of nuclear factor-κB (NF-κB) is necessary for tumour progression,
NF-κB may be an important pharmacological target for this disease. Our study aimed to evaluate the antitumour
effects of parthenolide, a NF-κB inhibitor, in two human glioblastoma cell lines (U87MG and U373) and in
glioblastoma xenografts. Furthermore, we aimed to investigate the molecular mechanisms underlying these effects.
Methods: The anti-invasive and anti-angiogenic effects of parthenolide were analysed using in vitro invasion and
angiogenesis assays. Parthenolide-induced growth inhibition of glioblastoma cells in vitro was determined using
the MTT (methyl thiazolyl tetrazolium) assay. In addition, the effect of parthenolide on orthotropic implantation
in vivo was evaluated using an intracerebral human glioblastoma xenograft model.
Results: We found that parthenolide suppresses proliferation, invasion, and tumour- induced angiogenesis of
glioblastoma cells. Molecular studies demonstrated that parthenolide suppresses gene and protein expression of
angiogenic factors. Furthermore, parthenolide reduced Akt phosphorylation and activated mitochondrial signalling,
suggesting that the antitumour function of parthenolide may be mediated not only by the inhibition of NF-κB but
also by the inhibition of Akt signalling and the activation of apoptotic proteins. Parthenolide suppressed
neovascularity and tumour growth in glioblastoma xenografts.
Conclusion: The present study identified parthenolide as a new therapeutic agent for glioblastomas.
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The serine/threonine kinase Akt, a downstream effector
of phosphatidylinositol 3-kinase (PI3K), is involved in
cell survival and anti-apoptotic signalling [1]. In a variety
of human tumours, including glioblastoma, Akt is con-
stitutively activated due to mutation or deletion of the
phosphatase and tensin homologue (PTEN), a major
negative regulator of the PI3K/Akt signal pathway [2,3].
The PTEN mutation frequency in glioblastoma is
reported to be as high as 80% [3]. Recent studies have
demonstrated that PI3K/Akt induction of cell survival* Correspondence: blue_flare17@yahoo.co.jp
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distribution, and reproduction in any mediumsignals is mediated, in part, through the activation of the
nuclear factor kappa B (NF-κB) transcription factor [4].
NF-κB is linked to various signal transduction pathways
and to transcription activation events that mediate cell
proliferation, cell migration, and angiogenesis [5,6].
Among NF-κB-regulated genes [7], matrix metallopro-
teinase (MMP)-9 is closely associated with tumour inva-
sion and tumour-induced angiogenesis, and vascular
endothelial growth factor (VEGF) promotes tumour-
induced angiogenesis. Therefore, inhibition of NF-κB
may serve as an effective treatment strategy for many
tumours through MMP-9 and VEGF downregulation
and disruption of Akt signalling.
Parthenolide, a major sesquiterpene lactone from the
plant Tanacetum parthenium, inhibits NF-κB bothMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ectly, by modifying p65 at a key cysteine residue in its
activation loop [8,9]. Due to its anti-inflammatory and
low toxicity properties, parthenolide has been used to
treat migraine and rheumatoid arthritis [10]. In addition,
many studies have investigated the effect of parthenolide
treatment on human malignancies [5-7,9], although only
two have examined the effect of parthenolide on glio-
blastoma cell proliferation in vitro [11,12]. However,
their results were contradictory. Anderson et al. reported
that parthenolide inhibition of glioblastoma cell prolif-
eration is independent of the NF-κB pathway [11]. In
contrast, Zanotto-Filho et al. reported that parthenolide-
induced glioblastoma cell death is mediated by NF-κB
inhibition [12]. We, therefore, aimed to clarify the mech-
anism involved in parthenolide inhibition of glioblast-
oma cell proliferation in vitro, and to examine the
in vivo effect of parthenolide on tumour growth by using
a xenograft model of glioblastoma. We also aimed to
evaluate the effect of parthenolide on invasion capacity
and tumour-induced angiogenesis in the PTEN-mutant
human glioblastoma cell lines U87MG [13] and U373
[14]. To the best of our knowledge, this study is the first
to investigate the antitumour effects of parthenolide on
human glioblastoma in vivo, and to define the anti-
invasive and anti-angiogenic effects of parthenolide
treatment on glioblastoma cells in vitro.
Methods
Cell cultures and drug
PTEN-mutant human glioblastoma cell lines, U87MG
and U373, were obtained from the American Type Cul-
ture Collection (Rockville, MD). Glioblastoma cells were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM; Gibco, Gaithersburg, MD) supplemented with
10% foetal bovine serum (FBS; Gibco), penicillin (100
unit/mL), and streptomycin (100 mg/mL). Human brain
microvascular endothelial cells (HBMECs) were pur-
chased from Science Cell Research Laboratories (Carlsbad,
CA) and maintained in RPMI 1640 (Gibco) supplemented
with 10% FBS, 10% NuSerum (BD Bioscience, Mountain
View, CA), modified Eagle’s medium nonessential amino
acids (1%) and vitamins (1%) (Gibco), sodium pyruvate
(1 mM), and EC growth supplement (30 μg/mL). Culture
flasks were coated with 0.2% type-I collagen to support
the growth of HBMEC monolayers, and experiments
were performed using passages 3–10. All cells were cul-
tured at 37°C in a humidified atmosphere containing
5% CO2.
Parthenolide was purchased from Sigma-Aldrich (St.
Louis, MO), dissolved in dimethyl sulphoxide (DMSO)
to a concentration of 10 mmol/L and stored in the dark
at −80°C. A sample of DMSO was stored under the same
conditions and used as a control treatment.ELISA based NF-κB transcription factor activity assay
Glioblastoma cells were treated with different concentra-
tions (0.1–50 μM) of parthenolide for 48 h, and then nu-
clear extracts were analysed using the TransAM NF-κB
p65 transcription factor assay kit (Active Motif, Carlsbad,
CA), according to the manufacturer’s recommendations.
NF-κB complexes were captured by binding to a consen-
sus 50-GGGACTTTCC-30 oligonucleotide immobilised on
a 96-well plate. Bound NF-κB was quantified by incubat-
ing with anti-p65 primary antibody followed by horserad-
ish peroxidase (HRP)-conjugated goat anti-rabbit IgG and
spectrophotometric detection at a wavelength of 450 nm.
Data were expressed as the percentage of NF-κB/DNA
binding relative to control cells. The assay was conducted
three times for each cell line.Methyl thiazolyl tetrazolium (MTT) assay
Glioblastoma cells (1 × 104 cells) were plated into 96-
well plates in 100 μL of DMEM containing 10% FBS.
HBMECs (1 × 104 cells) were plated into 96-well plates
in 100 μL of EGM-2 medium (Kurabo, Osaka, Japan)
containing 2% FBS. After 24 h, parthenolide was added
to each well at the indicated concentrations (0.1–50
μM). After 24 h or 48 h, 50 μL of MTT (2 mg/mL) was
added to each well and incubated at 37°C for a further
3 h. The 570 nm absorbance of the dissolved precipitate
was measured using a microplate reader. The cell prolif-
eration index was calculated as the ratio of the absorb-
ance of parthenolide-treated cells to that of control cells.
The assay was conducted three times for each cell line.In vitro invasion assay
In vitro invasion assay was performed using Transwell
invasion chambers (BioCoat; BD Biosciences). Glioblast-
oma cells were cultured in 24-well plates. An insert was
used to divide each well of the plate into lower and
upper chambers. The bottom of the insert comprised an
8.0-μm pore size PET membrane coated with Matrigel
(BD Biosciences). The lower chamber was filled with
700 μL of DMEM supplemented with 0.1% bovine serum
albumin (BSA) culture medium and human fibronectin
(12.5 μg/mL). Subconfluent glioblastoma cells were
harvested and resuspended in 500 μL of DMEM
supplemented with 0.1% BSA containing parthenolide
(1–50 μM), and 5.0 × 104 cells/well were added to the
upper chamber. After incubation for 23 h, the cells on
the upper surface of the filters were removed with cot-
ton swabs. Cells on the lower surface of the filters were
fixed using 70% ethanol, stained with Giemsa stain,
and five randomised fields were counted at 200× magni-
fication. The assay was conducted three times for each
cell line.
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co-culture method
A modified tube formation assay using culture inserts
was used to assess in vitro angiogenesis. Culture plates
(24-well) were coated with 300 μL/well Matrigel (BD
Biosciences) and polymerised at 37°C for 30 min.
HBMECs in 5% EBM-2 medium containing FBS were
plated (8 × 104 cells/well) into the coated wells, and an
insert plate containing a 1-μm pore PET membrane (Fal-
con HTS Multiwell Insert Systems, BD Biosciences) was
placed onto the plate. U87MG cells or U377 cells were
also cultured in the insert plate to allow soluble angio-
genic factors secreted from the glioblastoma cells to
reach the endothelial cells in the lower chambers.
Parthenolide (2.5-50 μM) was added to the culture
medium. After 7 days, four randomly selected fields of
cells from each treatment were digitally photographed,
and the length of the capillary-like structures within the
gel matrix was measured using ImageJ software (http://
rsb.info.nih.gov/ij/). The assay was conducted three
times for each cell line.
Western blot analysis
Akt phosphorylation was analysed in glioblastoma cells
by western blotting. Glioblastoma cells were starved in
serum-free condition for 24 h, stimulated with 5 ng/mL
PMA for 45 min, and then treated with parthenolide
(2.5–10 μM) for 2 h. Control cells were not stimulated
with PMA. Cells were harvested in buffer containing
50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA,
1% (v/v) Triton X-100, and protease and phosphatase
inhibitors (Sigma– Aldrich). Protein concentration was
measured using the Bradford assay with a BSA standard.
Cell lysate samples (50 μg) were separated by 10% SDS-
PAGE and transferred onto nitrocellulose membranes.
Membranes were incubated overnight at 4°C with anti-
phospho-Akt (Ser473) rabbit antibody (Cell Signalling
Technology, Danvers, MA) or total Akt rabbit antibody
(Cell Signalling Technology), incubated with HRP-
conjugated anti-rabbit IgG sheep antibody (GE Health-
care, Piscataway, NJ) for 1 h at room temperature, and
then, the proteins were visualised using a ECL+ Chemi-
luminescence kit (GE Healthcare).
To analyse the effect of parthenolide on Bcl-2 family
protein expression and caspase activation, glioblastoma
cells were in serum-free condition starved for 24 h, and
then treated with parthenolide (5 μM) for 6 h, 12 h, or
24 h. Bcl-2 family protein expression was assessed by
western blotting using anti-Bcl-2 rabbit antibody (Cell
Signalling Technology), anti-Bak rabbit antibody (Cell
Signalling Technology), and anti-Bax rabbit antibody
(Cell Signalling Technology) primary antibodies. Caspase
activation was assessed using rabbit anti-caspase 3 (Cell
Signalling Technology), rabbit anti-cleaved caspase 3 (CellSignalling Technology), rabbit anti-caspase 9 antibody
(Cell Signalling Technology), and rabbit anti-cleaved cas-
pase 9 (Cell Signalling Technology) antibodies.
β-Actin expression, detected using mouse anti-β-actin
monoclonal antibody (Sigma-Aldrich), was used as a
loading control. Western blot experiments were per-
formed at least twice, and protein expression was deter-
mined by quantitative densitometry.
Evaluation of VEGF and MMP-9 gene expression
The effect of parthenolide on VEGF and MMP-9 gene
expression was analysed by semi-quantitative RT-PCR.
Total cellular RNA was extracted from parthenolide-
treated (2.5, 5, or 10 μM; 12 h) glioblastoma cells
using an RNeasy Kit (Qiagen, Valencia, CA) according
to the manufacturer’s instructions. RT-PCRs were per-
formed using a Takara RNA PCR kit (AMV) ver. 3.0
(Takara, Shiga, Japan) according to the manufac-
turer’s protocol. PCR amplification was performed with
the following primers: VEGF forward, 50-CCATGA
ACTTTCTGCTGTCTT-30; VEGF reverse, 50-TCG-
ATCGTTCTGTATCAGTCT- 3; MMP-9 forward, 50-
GAATTCAGAACCAATCTCGACAGGCA-30; MMP-9
reverse, 50-GAATCC AGA ACCAATCTCACCGACAG-
GCA-30. As an internal control, a human GAPDH frag-
ment was amplified using the following primers:
forward, 50-TGTTGCCATCAATGACCC-30; and reverse,
50-GCAGAGATGATGACCCTT-30. RT-PCR was per-
formed in at least two independent experiments.
VEGF and MMP-9 secretion from glioblastoma cells
To determine the effect of parthenolide on the secretion
of VEGF and MMP-9 from glioblastoma cells, VEGF and
MMP-9 protein levels were measured in the culture
medium of parthenolide-treated (5 or 10 μM; 12 h) glio-
blastoma cells by using a VEGF and MMP-9 ELISA kit (GE
Healthcare). Data from parthenolide-treated cells were
expressed as percentage of untreated controls, and the
ELISA assay was conducted three times for each cell line.
Effect of parthenolide on orthotopic cell transplantation
Athymic female mice (BALB/c nu/nu), aged 6–8 weeks,
were obtained from Charles River Japan (Atsugi, Japan).
Mice were anaesthetised with an intraperitoneal injec-
tion of sodium pentobarbital (60 mg/kg), and then
injected intracerebrally with U87MG cells (1 × 105)
through a small hole drilled 2 mm anterior and 2 mm
lateral to the bregma. Starting immediately after tumour
cell transplantation, parthenolide (10 mgkg-1day-1) was
administered intraperitoneally to mice (n = 10) every
day. Control mice (n = 10) were treated with DMSO ve-
hicle. All mice were sacrificed on day 22, and their
brains were excised and snap-frozen in liquid nitrogen.
Growth of intracerebral tumours was confirmed by
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were cut using a cryo-microtome from the rostral to the
caudal edge of tumour-containing brain tissue. Tumour
size was estimated in sequential tumour sections by using
an Image-Pro system (Media Cybernetics Inc., Silver
Spring, MD). All procedures involving animals were
approved by the animal care committee of Kochi Univer-
sity and were done in accordance with institutional and
Japanese government guidelines for animal experiments.
Histological assessment of xenograft tumours
For immunohistological examination of xenograft tumours,
mice were treated as described above, and their brains
were harvested, fixed in buffered formalin, and embedded
in paraffin. Paraffin sections (4 μm) were deparaffinised
and dehydrated. MVD was assessed by counting the num-
ber of microvessels in one microscope field (at 200× mag-
nification) following haematoxylin-eosin (HE) staining.
Immunohistochemical staining for VEGF and MMP-9
was done by incubating paraffin sections with anti-VEGF
(Abcam Inc., Cambridge, MA) and anti-MMP-9 (Abcam
Inc.) antibodies, followed by incubation with HRP
(DAKO, Glostrup, Denmark) by using the EnVision+ Sys-
tem, and detection with diaminobenzidine. The percent-
age of VEGF and MMP-9 immunoreactive cells was
determined in 10 high-power microscopy fields.
Statistical analysis
The statistical significance of ELISA data was analysed
using an unpaired Student’s t-test. The results of inva-
sion and angiogenesis assays were statistically analysed
by one-way analysis of variance (ANOVA). The statis-
tical significance of differences in tumour volume be-
tween control and treated mice in the orthotopicFigure 1 NF-κB transcription factor activity. NF-κB transcriptional activit
parthenolide by using an ELISA-based assay. The assay showed that the tra
decreased as the concentration of parthenolide increased. Data is presente
p < 0.0001; ** indicates p < 0.01.implantation model was analysed using unpaired and
paired Student’s t-tests. For all statistical analyses, a p
value of <0.05 was considered to be statistically signifi-
cant. All values are presented as mean ± standard devi-
ation (SD).Results
Parthenolide suppresses NF-κB transcriptional activity
and inhibits tumour cell proliferation
In two glioblastoma cell lines treated with parthenolide,
we found that NF-κB transcriptional activity decreased as
parthenolide concentration increased (Figure 1; *, p <
0.0001; **, p < 0.01). Further, we used an MTT assay to
investigate the effect of parthenolide treatment on glio-
blastoma cell proliferation, and found that parthenolide
concentrations above 5 μM suppress the growth of glio-
blastoma cells in a dose-dependent manner (Figure 2; *,
p < 0.0001).Parthenolide suppresses tumour cell invasion and
tumour-induced angiogenesis in vitro
We evaluated the inhibitory effect of parthenolide on
tumour cell invasion by using U87MG cells (Figure 3A),
and observed that the numbers of invading cells
decreased as parthenolide concentration increased.
Therefore, glioblastoma cell invasion capacity is signifi-
cantly suppressed by parthenolide (Figure 3B; *, p <
0.0001; **, p < 0.01). We next evaluated the effect of
parthenolide on tumour-induced angiogenesis by using
the same cell line (Figure 4A), and found that increasing
parthenolide concentrations resulted in a significant de-
crease in tube length relative to control cells (Figure 4B;
*, p < 0.0001).y was analysed in glioblastoma cells 48 h after treatment with
nscriptional activity of NF-κB in the two glioblastoma cell lines
d as mean ± SD (n = 3). Points indicate bars + SD; * indicates
Figure 2 MTT assay. Glioblastoma cells were treated with parthenolide, and cell proliferation was assessed using the MTT assay. Parthenolide
inhibited the growth of glioblastoma cells at concentrations above 5 μM in a dose-dependent manner. Data is presented as mean ± SD (n = 3).
Points indicate bars + SD; * indicates p < 0.0001.
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expression and induces caspase activation and Bak
and Bax expression
We observed that a low basal level of Akt phosphoryl-
ation was present in glioblastoma cells in the absence of
PMA treatment, but that Akt phosphorylation was
strongly increased following PMA stimulation. However,
parthenolide treatment inhibited PMA-induced Akt
phosphorylation in a dose-dependent manner (Figure 5).
Furthermore, treatment with parthenolide inhibited Bcl-
2 protein expression, and increased Bak and Bax protein
expression (Figure 6A) and caspase-3 and caspase-9 acti-
vation (Figure 6B) in a dose-dependent manner.Figure 3 Matrigel invasion assay. Glioblastoma cells were treated with p
invasion assay. (A) Representative U87MG cell data. (B) Number of invading
decreased as the concentration of parthenolide increased. Bar = 100 μm. D
* indicates p < 0.0001; ** indicates p < 0.01.Parthenolide suppresses VEGF and MMP-9 gene and
protein expression
We found that parthenolide treatment of glioblastoma
cells significantly attenuates VEGF and MMP-9 mRNA
expression (Figure 7A) and reduces the secretion of
VEGF and MMP-9 protein into the culture medium
(Figure 7B; *, p < 0.0001).
Parthenolide suppresses neovascularisation and
xenograft tumour growth
Xenograft tumour volume was calculated from sequen-
tial histological sections (Figure 8A), and revealed that
the mean tumour volume in parthenolide-treated micearthenolide, and cell invasion was assessed using a Matrigel
glioblastoma cells relative to control. The number of invaded cells
ata is presented as mean ± SD (n = 3). Points indicate bars + SD;
Figure 4 In vitro angiogenesis assay. Glioblastoma cells were treated with parthenolide, and in vitro angiogenesis was assessed using a
modified tube formation assay. (A) Representative tube formation data. (B) Tube formation was significantly suppressed by parthenolide in a
dose-dependent manner. Data is presented as mean ± SD (n = 3). Points indicate bars + SD; * indicates p < 0.0001. Bar = 5 mm.
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animals (Figure 8B; 59.5 ± 3.80 mm3; *, p < 0.0001).
Histological evaluation of HE staining showed that the
mean MVD in parthenolide-treated mice (4.34 ± 0.89) is
significantly lower than in control mice (Figure 8C;
6.52 ± 0.95; p < 0.0001). Moreover, VEGF and MMP-9
expression is reduced in the xenografts of parthenolide-
treated mice relative to the controls (Figure 8C).Figure 5 Akt Phosphorylation. Glioblastoma cells were stimulated with P
analysed by western blotting. Representative blots are shown. Akt expressio
by PMA, but suppressed by parthenolide in a dose-dependent manner.Discussion
NF-κB plays a pivotal role in tumourigenesis and tumour
progression [5,6]. Aberrant or constitutively activated
NF-κB has been detected in human glioblastomas
[15,16]. The sesquiterpene lactone parthenolide inhibits
NF-κB by preventing the degradation of IκB-α and IκB-β
[17]. We investigated the anti-invasive and anti-
angiogenic effects of parthenolide on glioblastoma cellsMA prior to parthenolide treatment, and Akt phosphorylation was
n and phosphorylation in both glioblastoma cell lines was stimulated
Figure 6 Apoptosis-related protein expressions. The expression of apoptotic proteins in glioblastoma cells stimulated with PMA prior to
parthenolide treatment was assessed by western blotting. Representative blots are shown. (A) Analysis showed that parthenolide decreased the
protein expression of Bcl-2 and increased the protein expression of Bak and Bax in a dose-dependent fashion. (B) Analysis showed that
parthenolide induced the activation of caspase-3 and −9 in a dose-dependent manner.
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oma cell lines.
Glioblastoma invasion into normal brain tissues
involves disruption of the extracellular matrix (ECM)
and the subsequent penetration of tumour cells into ad-
jacent brain structures. This process is partly mediated
by the tumour secretion of MMPs, a group of enzymes
necessary for ECM degradation and involved in recon-
structing ECM components and accelerating tumour cell
migration [18]. Through their function as proteolytic
enzymes, MMPs destroy the collagen components of the
basement membrane (BM) and the ECM, thus disrupt-
ing intracellular adhesion, enabling tumour cell invasion,
and promoting tumour progression. Elevated levels of
MMPs, especially MMP-2 and MMP-9, correlate with
glioblastoma tumour aggressiveness, and are believed to
play an important role in tumour cell invasion [18-21].
In vivo and in vitro studies have revealed that the inhi-
biting MMP expression significantly reduces the invasive
capacity of glioblastoma cells [22]. Dimerisation of the
NF-κB transcription factor at the κB sequence in the
MMP-9 promoter initiates MMP-9 transcription, thus
upregulating MMP-9 protein expression [23]. Therefore,blocking NF-κB transcriptional activity by parthenolide
may inhibit glioblastoma cell invasion. We found that
parthenolide treatment inhibits both glioblastoma cell
invasion and MMP-9 expression. These data suggest that
parthenolide inhibition of glioblastoma cell invasion is
mediated by NF-κB inhibition.
Tumour-induced angiogenesis is critical for the growth
of solid tumours. Numerous studies have reported a cor-
relation between increased intratumour microvessel
density (MVD) and the risk of metastasis and/or
decreased survival of patients with solid tumours
[24-26]. NF-κB is an important upstream regulator of
VEGF [27], a major angiogenic factor that induces endo-
thelial cell proliferation. Glioblastomas are characterised
by a high level of angiogenesis, and both VEGF secretion
from tumour cells and TNF-alpha-induced NF-κB acti-
vation in endothelial cells promote endothelial cell sur-
vival by increasing anti-apoptotic gene expression under
conditions of serum starvation. These pathways may,
therefore, contribute to the maintenance of glioblastoma
angiogenesis [28]. Aberrant MMP-9 expression is also
implicated in the glioblastoma angiogenesis process.
Low basal MMP-9 expression occurs in normal brain
Figure 7 Expression of MMP-9 and VEGF. (A) Glioblastoma cells were treated with parthenolide, and MMP-9 and VEGF gene expression
was analysed by semi-quantitative RT-PCR. Parthenolide attenuated the mRNA expression of MMP-9 and VEGF compared with the control.
(B) Secretion of MMP-9 and VEGF protein from parthenolide-treated glioblastoma cells was assessed by ELISA. ELISA analysis showed that
parthenolide decreased the protein levels of VEGF and MMP-9 in the culture media of glioblastoma cell. Representative data are shown for both
assays. * indicates p < 0.0001.
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glioblastomas, and are linked to increased tumour cell
proliferation [29]. We found that parthenolide sup-
presses both tumour cell-induced angiogenesis and ex-
pression of the NF-κB targets, i.e., VEGF and MMP-9, in
glioblastoma cells. These data suggest that parthenolidesuppresses tumour-induced angiogenesis through NF-κB
inhibition.
With regard to tumor proliferation, we observed that
parthenolide inhibits glioblastoma cell proliferation in
dose-dependent manner. In the present study, cell viabil-
ity (MTT assay/48h) of U87MG cells decreased to 85 %
Figure 8 Xenograft mouse model. The effect of parthenolide on in vivo glioblastoma growth was determined using an intracerebral
glioblastoma xenograft mouse model. (A) Representative coronal section of mouse brain implanted by glioblastoma cells. (B) Tumour volume
analysis revealed that mean tumour volume of the parthenolide group (45.2 ± 2.74 mm3) was significantly smaller than that of the control group
(59.5 ± 3.80 mm3). * indicates p < 0.0001. (C) In immunohistochemical stainings VEGF and MMP-9 can be depicted by brown DAB staining
(VEGF-positive cell; arrow head, MMP-9-positive cell; white arrow head. Histological evaluation showed that the number of microvessel (arrow) and
the expression of VEGF and MMP-9 was significantly lower in the tumours from parthenolide-treated and control mice (p < 0.0001).
Bar = 200 μm.
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lide, respectively, compared to the control. Zanotto-
Filho et al. also reported that parthenolide inhibits
glioblastoma cell proliferation in dose-dependent fashion
and that NF-κB inhibition by parthenolide significantly
correlated in decreases in cell viability of glioblastoma
cells [12]. In their report, cell viability (MTT assay/36h)
of U138MG cells decreased to 88 % and 34%, after the
addition of 5 and 25 μM parthenolide, respectively, com-
pared to the control. Our results were close to their re-
search data. On the contrary, Anderson et al. performed
proliferation assay using not the MTT but the CCK8 re-
agent. They reported that cell viability (CCK8 assay/24h)
of U87MG cells decreased to about 78% and about 68%,
after the addition of 5 and 10 μM parthenolide, respect-
ively, compared to the control and that the inhibitory ef-
fect reached the plateau even if the concentration of
parthenolide was raised exceeding 20 μM [11]. And they
also reported that parthenolide was only able to suppress
NF-κB activity by 20-30%. The reason why the inhibitory
effect reached the plateau was not clarified. On the other
hand, we agree with their opinion that another pathway
other than NF-κB is also involved in antitumor effect of
parthenolide.By the way, NF-κB mediates the expression of anti-
apoptotic and pro-apoptotic proteins. And most studies
have attributed parthenolide suppression of tumour cell
proliferation to the induction of apoptotic proteins
mediated by NF-κB inhibition. In colorectal cancer cells,
for example, conformational changes in Bax and upregu-
lation of Bak lead to mitochondrial dysfunction and the
induction of apoptosis [30]. Recent reports suggest that
multiple pathways are involved in parthenolide-induced
apoptosis in human cancer cells, including oxidative
stress, intracellular thiol depletion, endoplasmic reticulum
stress, caspase activation, and mitochondrial dysfunction
[31-33]. In addition, parthenolide inhibition of c-Jun
N-terminal kinase (JNK) sensitises JB6 murine epidermal
cells to ultraviolet B (UVB)-induced apoptosis, suggest-
ing an anti-apoptotic role for JNK [34]. Another report
suggests that parthenolide- induced transcriptional sup-
pression of pro-apoptotic genes is mediated by STAT in-
hibition and acts at both the transcriptional level and by
direct inhibition of IKK-β [35].
In the present study, we used U87MG and U373 glio-
blastoma cells containing constitutively activated NF-κB
due to PTEN mutation to examine cell survival and
apoptosis. We demonstrated that parthenolide inhibits
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vates caspase-3 and caspase-9. These results suggest that
parthenolide induces apoptosis in glioblastoma cells by
activating the mitochondrial apoptosis cascade and redu-
cing survival signals through the inhibition of the Akt
pathway. Parthenolide was previously reported to induce
apoptosis in colorectal cancer and cholangiocarcinoma
cells via the mitochondrial pathway [30,36]. In contrast,
NF-κB inhibition by parthenolide markedly enhances the
sensitivity of resistant breast cancer tumour cells to tam-
oxifen through suppression of the Akt pathway [37].
Taken together, the pro-apoptotic effect of parthenolide
includes both stimulating the intrinsic apoptotic pathway
and modulating expression of Bcl-2 family proteins.
In our in vivo study, parthenolide inhibited the growth
of transplanted glioblastoma cells in mouse xenografts.
This suggests that inhibitory effect of parthenolide on
PTEN-mutant glioblastoma cells is caused by a combin-
ation of three mechanisms: suppression of tumour cell
invasion, suppression of angiogenesis, and induction of
tumour cell apoptosis.
We investigated tumour-induced angiogenesis by
using a new in vitro angiogenesis assay that measures
EC tube formation in collagen gels. Tumour-induced
angiogenesis is usually examined by adding tumour cell
medium directly to ECs without direct contact between
the endothelial and tumour cells. In contrast, the new
method allows the exchange of secreted factors between
the endothelial and tumour cells. HUVECs have been
used for many angiogenesis studies, especially those in-
cluding in vitro experiments. However, microvascular
endothelial cells from the organ being studied are pre-
sumed to be the most appropriate tool for tumour
angiogenesis assays. Therefore, for the first time, we
investigated the effect of parthenolide on angiogenesis
by using HBMECs.
The effect of parthenolide treatment on neuro-
inflammatory disorders has been examined in the recent
years [38-40]. Runmel et al. investigated the potential of
parthenolide to reduce brain inflammation and reported
that parthenolide can cross the blood–brain barrier [40].
Thus, the combined antitumour and anti-inflammatory
properties of parthenolide make it a promising candidate
for further studies of neurological diseases.Conclusion
We report that parthenolide inhibits tumour progression
in PTEN-mutant glioblastoma cells in vitro and in vivo,
and suggest that parthenolide has a therapeutic potential
as an antitumour agent for glioblastoma.Competing interests
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